York Pharma plc: Acquisition and financing

London, UK, 4 July 2008  York Pharma (AIM:YRK), the AIM listed specialist dermatology pharmaceutical company, announces today that it has acquired the sales and worldwide commercial rights to two leading dermatological/wound care products, Flammazine® and Flammacerium®, from Solvay Pharmaceuticals B.V. ('Solvay') and has agreed terms for a financing package to fund the acquisiton and provide working capital for the enlarged group.